Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients - ACR Meeting Abstracts

Abstract Number: 1006

Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients

Fernanda Genre¹, Javier Rueda-Gotor ¹, Sara Remuzgo-Martinez ¹, Veronica Pulito-Cueto ¹, Alfonso Corrales ¹, Veronica Mijares ¹, Leticia Lera-Gomez ¹, Virginia Portilla ¹, Rosa Expósito ², Cristina Mata ², Iván Ferraz-Amaro ³, Vanesa Hernández-Hernández ³, Santos Castañeda ⁴, Esther Vicente-Rabaneda ⁵, Cristina Fernández-Carballido ⁶, M. Paz Martínez-Vidal ⁷, David Castro-Corredor ⁸, Joaquín Anino-Fernández ⁸, Juan Quevedo-Abeledo ⁹, Carlos Rodríguez-Lozano ⁹, Ricardo Blanco ¹⁰, María Luz García-Vivar ¹¹, Eva Galíndez-Agirregoikoa ¹¹, Javier Llorca ¹², Raquel López-Mejías ¹ and Miguel Angel González-Gay ¹³, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Comarcal de Laredo, Laredo, Spain, Laredo, Spain, ³Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario La Princesa, Madrid, Spain, ⁶Rheumatology Division, Hospital Universitario San Juan de Alicante, Alicante, Spain, Alicante, Spain, ⁷Rheumatology Division, Hospital General Universitario de Alicante, Alicante, Spain, Alicante, Spain, ⁸Rheumatology Division, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, Ciudad Real, Spain, ⁹Rheumatology Division, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, Las Palmas de Gran Canaria, Spain, ¹⁰Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ¹¹Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ¹²School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, Santander, Spain, ¹³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, biomarkers and atherosclerosis

Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Vaspin is a novel adipokine with insulin-sensitizing functions that exerts anti-inflammatory actions^1,2. It has been associated with cardiovascular (CV) disease, CV risk factors and inflammation in the general population and in chronic inflammatory conditions different from axial SpA (axSpA)^2-4. In particular, it has been suggested that vaspin may act as a compensatory mechanism for inflammation and CV disease^1,3. This could be relevant for axSpA, given the high incidence of CV disease (mainly due to accelerated atherosclerosis) exhibited by these patients^5,6, which turns this comorbidity into a matter of major concern among rheumatologists. However, data on the role of vaspin regarding surrogate markers of atherosclerosis in the context of axSpA is scarce. For this reason, we aimed to evaluate the implication of vaspin in subclinical atherosclerosis in axSpA at the genetic and protein level.

Methods: This study included 385 patients that fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA⁷. Clinical data was retrieved from medical records. Carotid US was performed to evaluate the presence of subclinical atherosclerosis (carotid plaques and abnormal carotid intima-media thickness [cIMT] values). 3 polymorphisms of vaspin (rs2236242, rs35262691 and rs7159023), previously associated with CV risk factors and/or reported as functional gene variants, were genotyped by TaqMan probes. Serum vaspin levels were assessed by ELISA. Statistical analysis was performed using STATA® v. 11.1, adjusting the results by potential confounding factors.

Results: We disclosed that the C allele of rs35262691 conferred a higher risk of developing carotid plaques in axSpA (p< 0.05)(Table 1). Regarding serum vaspin levels, even if they showed no statistically significant association with carotid plaques or cIMT values, these values positively correlated with factors associated with high CV risk such as systolic blood pressure (p=0.02) and waist circumference (p=0.03). Furthermore, serum vaspin levels were significantly higher in female patients than in males (p< 0.001).

Conclusion: Our results show for the first time that vaspin rs35262691 polymorphism is associated with carotid plaques in axSpA. The relevance of this molecule in the atherosclerotic process is further demonstrated by the relationship between serum levels and CV risk factors. All these data support a key role of vaspin in atherosclerosis in axSpA.

[1] Wang HH, et al. Braz J Med Biol Res. 2016;49(7):e5231. [2] Esaki E, et al. Atherosclerosis. 2014;233(1):248-52. [3] El-Lebedy DH, et al. Diabetes Metab Syndr. 2018;12(5):643-8. [4] Senolt L, et al. Ann Rheum Dis. 2010;69(7):1410-1. [5] Rueda-Gotor J, et al. Clin Exp Rheumatol. 2015;33:315–20. [6] Papagoras C, et al. Joint Bone Spine. 2014;81(1):57–63. [7] Rudwaleit M, et al. Ann Rheum Dis. 2009;68(6):777–83.

This work was supported by funds of a NEXT-VAL grant (NVAL17/10)(IDIVAL) awarded to FG. SR-M is supported by RD16/0012/0009 (RETICS Program, ISCIII). VP-C is supported by PREVAL18/01 (IDIVAL). RL-M and VM are supported by CP16/00033 (Miguel Servet type I programme, ISCIII).

Table 1 Vaspin

Table 1. Association between vaspin rs35262691 polymorphism and presence/absence of carotid plaques in patients with axSpA.

Disclosure: F. Genre, None; J. Rueda-Gotor, None; S. Remuzgo-Martinez, None; V. Pulito-Cueto, None; A. Corrales, None; V. Mijares, None; L. Lera-Gomez, None; V. Portilla, None; R. Expósito, None; C. Mata, None; I. Ferraz-Amaro, None; V. Hernández-Hernández, None; S. Castañeda, None; E. Vicente-Rabaneda, None; C. Fernández-Carballido, None; M. Martínez-Vidal, None; D. Castro-Corredor, None; J. Anino-Fernández, None; J. Quevedo-Abeledo, None; C. Rodríguez-Lozano, None; R. Blanco, AbbVie, 2, 5, 8, AbbVie, MSD, Roche, Pfizer, Bristol-Myers, Janssen., 2, 8, Bristol-Myers Squibb, 5, 8, Janssen, 5, 8, MSD, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8; M. García-Vivar, None; E. Galíndez-Agirregoikoa, None; J. Llorca, None; R. López-Mejías, None; M. González-Gay, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 2, 5, EliLilly, 2, 5, Jansen, 2, Janssen, 2, MSD, 2, 5, 8, Novartis, 2, 5, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, Sobi, 5, 8.

To cite this abstract in AMA style:

Genre F, Rueda-Gotor J, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Mijares V, Lera-Gomez L, Portilla V, Expósito R, Mata C, Ferraz-Amaro I, Hernández-Hernández V, Castañeda S, Vicente-Rabaneda E, Fernández-Carballido C, Martínez-Vidal M, Castro-Corredor D, Anino-Fernández J, Quevedo-Abeledo J, Rodríguez-Lozano C, Blanco R, García-Vivar M, Galíndez-Agirregoikoa E, Llorca J, López-Mejías R, González-Gay M. Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/vaspin-rs35262691-is-associated-with-atherosclerotic-disease-in-axial-spondyloarthritis-patients/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vaspin-rs35262691-is-associated-with-atherosclerotic-disease-in-axial-spondyloarthritis-patients/

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].